Text Size

In Vitro Study of Peripheral Blood Mononuclear Cell Function in Healthy Individuals and Patients

This study has been completed.
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00342485
First received: June 19, 2006
Last updated: March 7, 2008
Last verified: March 2008
History of Changes
  Purpose

Peripheral blood mononuclear cells (PBMC) will be collected from healthy volunteers and patients who present with different diseases that involve or implicate the immune system dysregulation (HIV infection, autoimmune diseases and cancer). These PBMC will be studied in vitro for a number of functional parameters, including generating soluable factors that inhibit HIV infection, developing patterns of immune dysregulation, and inducing apoptotic T cell death. The purpose of such studies is to obtain insight into the mechanisms of natural resistance to viral infections, AIDS pathogenesis, and disease-induced immune dysregulation.


Condition
Cell Function

Study Type: Observational
Official Title: In Vitro Study of Peripheral Blood Mononuclear Cell Function in Healthy Individuals and Patients

Resource links provided by NLM:

MedlinePlus related topics: Cancer HIV/AIDS
U.S. FDA Resources

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 5000
Study Start Date: April 1993
Estimated Study Completion Date: March 2008
Detailed Description:

Peripheral blood mononuclear cells (PBMC) will be collected from healthy volunteers and patients who present with different diseases that involve or implicate the immune system dysregulation (HIV infection, autoimmune diseases and cancer). These PBMC will be studied in vitro for a number of functional parameters, including generating soluable factors that inhibit HIV infection, developing patterns of immune dysregulation, and inducing apoptotic T cell death. The purpose of such studies is to obtain insight into the mechanisms of natural resistance to viral infections, AIDS pathogenesis, and disease-induced immune dysregulation.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA:

Greater than or equal to 18 years old.

Documented HIV infection by current DoD criteria (1 ELISA, 2 Confirmatory Western Blot) or by one of the following tests; DNA PCR, RNA PCR, p24 antigen test, viral culture assay.

CD4 lymphocyte cell count greater than 300 mm(3).

EXCLUSION CRITERIA:

Unable to provide informed consent.

Unable to meet the minimum (150 days) and maximum (395 days) research visit interval requirements.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00342485

Locations
United States, Texas
Willford Hall USAF Medical Center
San Antonio, Texas, United States, 78236
Sponsors and Collaborators
National Cancer Institute (NCI)
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00342485     History of Changes
Other Study ID Numbers: 999993010, OH93-NC-N010
Study First Received: June 19, 2006
Last Updated: March 7, 2008
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Cellular Immunity
HIV-infected
Immune Deficiency
Cancer
Transplantation

ClinicalTrials.gov processed this record on May 19, 2013